NeuroPace, Inc. (NPCE)

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

NeuroPace FDA Bid for Expanded Epilepsy Use Stalls as Agency Seeks More Data

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now

NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?

NPCE Explains How NeuroPace's RNS System Makes Money